Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Kathleen M. Dungan MD, MPH Advisory Board

Silvio E. Inzucchi MD Editor-in-Chief

See All Experts

story of the week

Published in Diabetes and

Journal Scan / Research · March 10, 2021

RCT of Semaglutide in Adults With Overweight or Obesity, and Type 2 Diabetes

The Lancet

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Vanita Aroda MD

The Lancet

Semaglutide 2·4 MG Once a Week in Adults With Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial

Lancet 2021 Mar 02;[EPub Ahead of Print], M Davies, L Færch, OK Jeppesen, A Pakseresht, SD Pedersen, L Perreault, J Rosenstock, I Shimomura, A Viljoen, TA Wadden, I Lingvay

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

RCT of Semaglutide in Adults With Overweight or Obesity, and Type 2 Diabetes

Additional Info

Semaglutide 2·4 MG Once a Week in Adults With Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial

Further Reading

Association of Early Post-Transplantation Hyperglycaemia and Diabetes Mellitus on Outcomes Following Heart Transplantation

Associations of Diabetes and Prediabetes With Mortality and Life Expectancy in Chinese Individuals

Glycemic Threshold Above Which Improvements in β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Individuals With Early Type 2 Diabetes

Racial and Ethnic Disparities in Early Glycemic Control Trends Among Veterans With Newly Diagnosed Type 2 Diabetes

Characterizing the Effects of Using GLP-1 Receptor–Based Agonists on Body Composition

Once-Weekly Semaglutide in Individuals With Obesity and Knee Osteoarthritis

Efficacy of Vitamin D Supplementation on Glycaemic Control in Individuals With Type 2 Diabetes

The SEAD Program Improved Clinical Outcomes in Underserved Young Adults With Type 1 Diabetes

Effects of Semaglutide Use on Obesity in Patients Undergoing Dialysis for Kidney Failure

Risk of Complications and Mortality Rates Among Individuals With Younger- vs Later-Onset Type 2 Diabetes

Regional Heterogeneity in the Efficacy of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes

Recently Updated